NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
Clinical Trials
33 trialsNCT03425331 2026-01-08
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04966676 2026-01-08
ATLAS
University Health Network, Toronto
Phase 2 Terminated
NCT05199285 2025-10-03
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Academic and Community Cancer Research United
Phase 2 Terminated
NCT06790303 2025-06-04
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
Phase 2 Terminated
NCT05200143 2024-09-19
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Providence Health & Services
Phase 2 Terminated
NCT03552380 2024-09-03
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05116917 2024-05-28
INFLUENCE
Herlev Hospital
Phase 2 Terminated
NCT02978443 2024-04-04
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Georgetown University
Phase 2 Terminated
NCT04899921 2024-03-26
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03461952 2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2 Terminated
NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04894994 2023-12-05
FLX475 in Combination With Ipilimumab in Advanced Melanoma
RAPT Therapeutics, Inc.
Phase 2 Terminated
NCT01377389 2023-09-29
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02054520 2023-04-18
Immunotherapy Study for Patients With Stage IV Melanoma
Lumos Pharma
Phase 2 Terminated
NCT03406715 2023-03-30
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03430791 2023-02-02
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Baptist Health South Florida
Phase 2 Terminated
NCT04088500 2023-01-10
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
Bristol-Myers Squibb
Phase 2 Terminated
NCT03430063 2022-11-03
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03693846 2022-10-20
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT00140855 2022-10-12
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
Ludwig Institute for Cancer Research
Phase 2 Terminated
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT04258150 2022-03-31
TRIPPLE-R
Herlev Hospital
Phase 2 Terminated
NCT02506114 2021-11-24
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02009384 2021-10-25
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
University of Louisville
Phase 2 Terminated
NCT02097732 2021-05-12
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03724968 2021-04-20
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT02892734 2020-07-16
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Northwestern University
Phase 2 Terminated
NCT01970527 2020-02-13
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
University of Washington
Phase 2 Terminated
NCT01689974 2018-02-23
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
NYU Langone Health
Phase 2 Terminated
NCT01696045 2017-08-29
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Bristol-Myers Squibb
Phase 2 Terminated
NCT01709162 2015-11-30
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Terminated